Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
3.
18th International Conference on Scientometrics and Informetrics (ISSI) ; : 1511-1512, 2021.
Article in English | Web of Science | ID: covidwho-1498760
4.
Chinese Traditional and Herbal Drugs ; 52(17):5339-5349, 2021.
Article in Chinese | EMBASE | ID: covidwho-1408667

ABSTRACT

Panax ginseng is a traditional medicinal and edible plant with multiple physiological functions. It is one of the most widely used Chinese herbal medicines in clinic. It is known as the "king of herb". Prescriptions containing the Ginseng as their principal ingredient such as Renshenbufei Decoction and Shenmai injection are widely used in traditional Chinese Medicine. In addition, a large number of studies have shown that ginseng and its preparations have pharmacological effects such as anti-atherosclerosis, anti-myocardial ischemia, anti-tumor and anti-liver fibrosis. With the outbreak of novel coronavirus pneumonia, Traditional Chinese Medicine is widely applied in clinical and experimental studies on lung injury protection. It is found that they possess good curative effects on various lung diseases. However, the material basis and mechanism of their prevention and treatment on lung diseases are uncertain. The main active components of ginseng are the material basis of bioactivity of ginseng. The present review summarized the effects and mechanisms of ginseng and its preparations in the treatment of lung diseases via its functional components, which will provide a reference for the further study of ginseng and its preparations in anti-pulmonary disease and clinical treatments.

5.
Zhonghua Jie He He Hu Xi Za Zhi ; 44(3): 230-236, 2021 Mar 12.
Article in Chinese | MEDLINE | ID: covidwho-1134266

ABSTRACT

Objective: To explore a modified CT scoring system, its feasibility for disease severity evaluation and its predictive value in coronavirus disease 2019 (COVID-19) patients. Methods: This study was a multi-center retrospective cohort study. Patients confirmed with COVID-19 were recruited in three medical centers located in Beijing, Wuhan and Nanchang from January 27, 2020 to March 8, 2020. Demographics, clinical data, and CT images were collected. CT were analyzed by two emergency physicians of more than ten years' work experience independently through a modified scoring system. Final score was determined by average score from the two reviewers if consensus was not reached. The lung was divided into 6 zones (upper, middle, and lower on both sides) by the level of trachea carina and the level of lower pulmonary veins. The target lesion types included ground-glass opacity (GGO), consolidation, overall lung involvement, and crazy-paving pattern. Bronchiectasis, cavity, pleural effusion, etc., were not included in CT reading and analysis because of low incidence. The reviewers evaluated the extent of the targeted patterns (GGO, consolidation) and overall affected lung parenchyma for each zone, using Likert scale, ranging from 0-4 (0=absent; 1=1%-25%; 2=26%-50%; 3=51%-75%; 4=76%-100%). Thus, GGO score, consolidation score, and overall lung involvement score were sum of 6 zones ranging from 0-24. For crazy-paving pattern, it was only coded as absent or present (0 or 1) for each zone and therefore ranging from 0-6. Results: A total of 197 patients from 3 medical centers and 522 CT scans entered final analysis. The median age of the patients was 64 years, and 54.8% were male. There were 76(38.8%) patients had hypertension and 30(15.3%) patients had diabetes mellitus. There were 75 of the patients classified as moderate cases, as well as 95 severe cases and 27 critical cases. As initial symptom, dry cough occurred in 170 patients, 134 patients had fever, and 125 patients had dyspnea. Reparatory rate, oxygen saturation, lymphocyte count and CURB 65 score on admission day varied among patients with different disease severity scale. There were 50 of the patients suffered from deterioration during hospital stay. The median time consumed for each CT by clinicians was 86.5 seconds. Cronbach's alpha for GGO, consolidation, crazy-paving pattern, and overall lung involvement between two clinicians were 0.809, 0.712, 0.678, and 0.906, respectively, showing good or excellent inter-rater correlation. There were 193 (98.0%) patients had GGO, 147 (74.6%) had consolidation, and 126(64.0%) had crazy-paving pattern throughout clinical course. Bilateral lung involvement was observed in 183(92.9%) patients. Median time of interval for CT scan in our study was 7 days so that the whole clinical course was divided into stages by week for further analysis. From the second week on, the CT scores of various types of lesions in severe or critically patients were higher than those of moderate cases. After the fifth week, the course of disease entered the recovery period. The CT score of the upper lung zones was lower than that of other zones in moderate and severe cases. Similar distribution was not observed in critical patients. For moderate cases, the ground glass opacity score at the second week had predictive value for the escalation of the severity classification during hospitalization. The area under the receiver operating characteristic curve was 0.849, the best cut-off value was 5 points, with sensitivity of 84.2% and specificity of 75.0%. Conclusions: It is feasible for clinicians to use the modified semi-quantitative CT scoring system to evaluate patients with COVID-19. Severe/critical patients had higher scores for ground glass opacity, consolidation, crazy-paving pattern, and overall lung involvement than moderate cases. The ground glass opacity score in the second week had an optimal predictive value for escalation of disease severity during hospitalization in moderate patients on admission. The frequency of CT scan should be reduced after entering the recovery stage.


Subject(s)
COVID-19 , Lung/diagnostic imaging , Radiography, Thoracic/standards , Tomography, X-Ray Computed/methods , China , Female , Humans , Male , Predictive Value of Tests , Radiography, Thoracic/methods , SARS-CoV-2 , Spatial Analysis
6.
Chinese Traditional and Herbal Drugs ; 51(9):2379-2389, 2020.
Article in Chinese | EMBASE | ID: covidwho-682681

ABSTRACT

Clinical practice since the outbreak of the novel coronavirus disease (COVID-19) has proven that the prevention and control measures of traditional Chinese medicine and the integrated treatment of traditional Chinese and Western medicine in China have effectively controlled the epidemic situation. Up to March 6 in 2020, Chinese medicine participated in the treatment of nearly 60 000 confirmed cases, and more than 20 000 were cured and discharged. In the critical period, the frequency of use of ginseng in the distribution of prescriptions, Chinese patent medicines and drug compatibility accounted for 56.41% of the drug distribution. According to the classification of ginseng compound, ginseng compound or ginseng single herb integrated with other antiviral drugs, ginseng extract, and ginsenosides, this article reviews the literature reports on ginseng prescriptions, ginseng and its saponins in the prevention and treatment of viral diseases, and related antiviral mechanisms, etc, with view to providing scientific basis for the use of ginseng and its saponins to prevent and treat viral diseases such as novel coronavirus pneumonia.

7.
Zhonghua Xue Ye Xue Za Zhi ; 41(4): 302-307, 2020 Apr 14.
Article in Chinese | MEDLINE | ID: covidwho-370588

ABSTRACT

Objective: To investigate the clinical and coagulation characteristics in patients with critical Coronavirus disease 2019 (COVID-19) and acro-ischemia. Methods: The retrospective study included 7 critical COVID-19 patients with acro-ischemia in an intensive care unit (ICU) in Wuhan, from Feb 4 to Feb 15, 2020. The clinical and laboratory data before and during the ICU stay were analyzed. Results: The median age of 7 patients was 59 years and 4 of them were men. Three patients were associated with underlying comorbidities. Fever, cough, dyspnea and diarrhea were common clinical symptoms. All patients had acro-ischemia presentations including finger/toe cyanosis, skin bulla and dry gangrene. D-dimer, fibrinogen and fibrinogen degradation product (FDP) were significantly elevated in most patients. Prothrombin time was prolonged in 4 patients. D-dimer and FDP levels progressively elevated consistent with COVID-2019 exacerbation. Four patients were diagnosed with disseminated intravascular coagulation (DIC) . Low molecular weight heparin (LMWH) was administrated in 6 patients, which reduced D-dimer and FDP rather than improved clinical symptoms. Five patients died finally and the median time from acro-ischemia to death was 12 days. Conclusions: Coagulation parameters should be monitored closely in critical COVID-2019 patients. The timing and protocol of anticoagulation therapy are still under investigation based on more clinical data.


Subject(s)
Anticoagulants/therapeutic use , Coronavirus Infections/complications , Heparin, Low-Molecular-Weight/therapeutic use , Ischemia/drug therapy , Pneumonia, Viral/complications , Betacoronavirus , COVID-19 , China , Coronavirus Infections/drug therapy , Female , Fibrin Fibrinogen Degradation Products/analysis , Humans , Ischemia/virology , Male , Middle Aged , Pandemics , Pneumonia, Viral/drug therapy , Retrospective Studies , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL